PR Newswire (Thu, 8:14AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
930 people get PRGO articles and Market Currents by email alert.
Get email alerts on PRGO »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (May 13, 2013)
-
PR Newswire (May 7, 2013)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 23, 2013)
-
PR Newswire (Apr 1, 2013)
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Feb 25, 2013)
-
PR Newswire (Feb 19, 2013)
-
PR Newswire (Feb 12, 2013)
To learn more about Seeking Alpha Pro, click here.
-
Perrigo Looks AttractiveRobert Freedland • Mon, Jun 13, 2011
-
Bullish on PerrigoZacks Investment Research • Tue, Mar 29, 2011
-
Why Puts Are Surging in PerrigooptionMONSTER • Wed, Sep 8, 2010
-
Perrigo Smiles at the FutureInvest With An Edge • Thu, Sep 17, 2009
-
Earnings Preview: PerrigoTheflyonthewall • Wed, Nov 5, 2008
-
Perrigo Picks Up On ProfitJohn C. Lee • Thu, Aug 21, 2008
-
FDA Approves Perrigo's Nicotine GumAaron Katsman • Fri, Apr 25, 2008
-
Eye on Perrigo CompanyVahan Janjigian • Sun, Apr 6, 2008
-
Perrigo: An Israeli Stock on SteroidsAaron Katsman • Mon, Nov 19, 2007
-
CADX To Receive $14.5M Or $0.15/Share In Non-Dilutive FundsPropThink • Wed, Dec 12, 2012
-
Top 5 Stocks With Insider Sells Filed On September 25 To ConsiderMarkus Aarnio • Wed, Sep 26, 2012
-
The 6 Best Seasonal Large Cap Healthcare Stocks To Own Through NovemberTodd Campbell • Tue, Sep 11, 2012
-
5 Stocks To Trade, What's Next For The MarketThe Oxen Group • Wed, Aug 29, 2012
-
Perrigo's CEO Discusses F4Q2012 Results - Earnings Call TranscriptThu, Aug 16, 2012
-
Perrigo's CEO Discusses Q3 2012 Results - Earnings Call TranscriptTue, May 8, 2012
-
Perrigo's CEO Discusses F2Q12 Results - Earnings Call TranscriptTue, Feb 7, 2012
-
Perrigo's CEO Discusses Q1 2012 Results - Earnings Call TranscriptThu, Oct 27, 2011
-
Perrigo's CEO Discusses Q4 2011 Results - Earnings Call TranscriptTue, Aug 16, 2011
-
Perrigo Company F2Q10 (Qtr End 12/26/09) Earnings Call TranscriptTue, Feb 2, 2010
-
Perrigo Company F4Q09 (Qtr End 06/27/09) Earnings Call TranscriptTue, Aug 18, 2009
-
Perrigo Company F3Q09 (03/28/09) Earnings Call TranscriptFri, May 8, 2009
-
The Perrigo Company F2Q09 (Qtr End 12/27/08) Call TranscriptTue, Feb 3, 2009
-
Perrigo Co. F1Q09 (Qtr. End 09/30/08) Earnings Call TranscriptFri, Nov 7, 2008
-
Perrigo Company F4Q08 (Qtr End 06/28/08) Earnings Call TranscriptMon, Aug 18, 2008
-
Perrigo Co. F3Q08 (Qtr End 3/29/08) Earnings Call TranscriptTue, May 6, 2008
-
Perrigo Co. F2Q08 (Qtr End 12/29/07) Earnings Call TranscriptWed, Feb 6, 2008
-
Perrigo F1Q08 (Qtr End 9/29/07) Earnings Call TranscriptThu, Nov 1, 2007
-
PR Newswire (Thu, 8:14AM)
-
PR Newswire (May 13, 2013)
-
at CNBC.com (May 9, 2013)
-
PR Newswire (May 7, 2013)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 23, 2013)
-
PR Newswire (Apr 1, 2013)
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Feb 25, 2013)
-
PR Newswire (Feb 19, 2013)
-
PR Newswire (Feb 12, 2013)
-
PR Newswire (Feb 5, 2013)
-
at MarketWatch.com (Feb 1, 2013)
-
at MarketWatch.com (Feb 1, 2013)
-
at MarketWatch.com (Feb 1, 2013)
-
PR Newswire (Feb 1, 2013)
-
PR Newswire (Feb 1, 2013)
-
PR Newswire (Feb 1, 2013)
PRGO vs. ETF Alternatives
Company Description
Perrigo Company, established in 1887, is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 11:39 AM Perrigo (PRGO -3.7%) takes a hit this morning after its FQ3 result misses across the board. Net earnings fell 3.3% Y/Y, as the pharmaceutical supplier was hit by higher input costs and a big jump in tax expenses, which masked a 19% increase in net sales. All product categories within the segment grew from the year earlier, with sales in the nutritionals business in particular rising 13% to $133.3M. Gross margin also edged up to 36% from 35.9%, despite total operating expenses widening by 15%. Comment! [Healthcare, Earnings, On the Move, Consumer]
- Tuesday, May 7, 7:48 AM Perrigo (PRGO): Q1 EPS of $1.42 misses by $0.02. Revenue of $919.8M (+18.2% Y/Y) misses by $15.64M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, May 7, 12:05 AM Notable earnings before Tuesday’s open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC 2 Comments [Earnings]
- Monday, May 6, 5:30 PM Notable earnings before Tuesday's open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC Comment! [Earnings]
- Thursday, May 2, 3:34 PM Perrigo Company (PRGO) declares $0.09/share quarterly dividend, in line with previous. Forward yield 0.30%. For shareholders of record May 31. Payable June 18. Ex-div date May 29. (PR) Comment! [Dividends]
- Monday, April 22, 10:22 AM Perrigo (PRGO +0.1%-) gets a slight boost this morning after JP Morgan ups the shares to Overweight and raised its price target from $120 to $132. The firm calls PRGO a "premium franchise" within its coverage universe, with Q3 potentially providing a number of positive catalysts to drive the shares higher, including the re-launch of its infant nutritional products and a rollout of its recently acquired store brand pet care offering. Comment! [Healthcare]
- Monday, February 25, 3:32 PM Perrigo Company (PRGO +1.8%) trades higher after UBS upped the shares to Buy earlier today on valuation. The firm cites optimism over its generic testosterone gel 1%, which is a generic version of AbbVie's (ABBV -2%) AndroGel 1%, a treatment for adult males who have low or no testosterone. Comment! [Healthcare, On the Move]
- Tuesday, February 5, 2:29 PM Perrigo (PRGO +1.6%) receives FDA approval to market its generic testosterone gel 1%. The product is a generic version of AbbVie's (ABBV +0.4%) AndroGel 1%, which is indicated to treat adult males who have low or no testosterone. Comment! [Healthcare, On the Move]
- Friday, February 1, 11:08 AM Perrigo (PRGO +5.3%) trades higher after its FQ2 results easily beat estimates this morning. Net earnings rose 6.2% Y/Y as the store-brand pharmaceutical and nutritional-products maker recorded strong revenue growth from its consumer health-care business, although margins narrowed on higher costs. The company also says it's bought pet-health company Velcera for $160M in an all-cash deal it's billed as a "natural extension" to its Sergeant's pet care product line. Comment! [Healthcare, Earnings, On the Move, M&A]
-
Friday, February 1, 9:10 AM
Premarket gainers: ADNC +30%. TSYS +15%. RAD +9%. CTRP +8%. EDAP +7%. ALU +6%. DELL +6%. VVUS +5%. PRGO +5%.
Losers: ECTE -35%. OTT -23%. LTM -16%. SDR -11%. OCZ -8%. CLSN -7%. ALKS -7%. NMM -6%. TLAB -5%. Comment! [On the Move] - Friday, February 1, 7:59 AM Perrigo (PRGO): FQ2 EPS of $1.36 beats by $0.05. Revenue of $883M beats by $1.16M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, February 1, 12:05 AM Notable earnings before Friday’s open: AON, BEAM, BEN, BPO, CVX, HCLP, IR, LM, LYB, MAT, MRK, NOV, NS, NWL, PRGO, TSN, WETF, XOM Comment! [Earnings]
- Thursday, January 31, 5:30 PM Notable earnings before Friday’s open: AON, BEAM, BEN, BPO, CVX, HCLP, IR, LM, LYB, MAT, MRK, NOV, NS, NWL, PRGO, TSN, WETF, XOM Comment! [Earnings]
- Thursday, January 31, 2:56 PM Perrigo Company (PRGO) declares $0.09/share quarterly dividend, in line with previous. Forward yield 0.36%. For shareholders of record Mar. 01. Payable Mar. 19. Ex-div date Feb. 27. (PR) Comment! [Dividends]
- Friday, December 28, 2012, 3:18 PM Perrigo Company (PRGO -0.8%) says it's acquired the remaining stake of privately held Cobrek Pharmaceuticals, in a deal worth approximately $45 million on a cash-free and debt-free basis. PRGO has had a collaborative agreement with the company since 2008, after buying an 18% interest to develop and market Cobrek's foam dosage form generic pharmaceutical products. Comment! [Healthcare, M&A]
- Wednesday, November 28, 2012, 10:01 AM Cadence Pharmaceuticals (CADX +3.4%) and Perrigo (PRGO -1.3%) settle a lawsuit over Cadence's Ofirmev injection for reducing fever and pain. Under the deal, Perrigo has the first right of refusal to market any generic version of Ofirmev in the U.S. should Cadence decide to authorize such a version. Perrigo will also be allowed to launch a copycat drug in 2020. (PR) Comment! [Healthcare]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.












